CervoMed Inc. Announces Late‑Breaking Presentation of Phase 2a Results

What Happened

• CervoMed Inc. filed an 8-K on September 10, 2026 disclosing that initial results from its Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia were accepted as a late‑breaking oral presentation at the Annual Meeting of the International Society of Frontotemporal Dementias (ISFTD), scheduled for October 8–11, 2026 in Philadelphia.
• The company also posted a corporate presentation on its website (Investors – Events and Presentations) under Regulation FD; company representatives may use that presentation in investor meetings and conferences.

Key Details

• Filing date: September 10, 2026 (Form 8‑K).
• Clinical program: Phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia.
• Conference: ISFTD Annual Meeting, Oct 8–11, 2026, Philadelphia — initial results accepted as a late‑breaking oral presentation.
• Press release attached as Exhibit 99.1 to the 8‑K; presentation material posted on www.cervomed.com (Investors – Events and Presentations).

Why It Matters

• Acceptance as a late‑breaking oral presentation signals that the company’s initial Phase 2a data will be publicly presented to specialists and researchers at a major neurology meeting, increasing visibility of the trial results to investors, clinicians, and potential partners.
• The Regulation FD posting makes management presentation materials broadly available, improving transparency about the company’s business, clinical studies and development plans; however, the company notes the presentation is summary information and may be updated only as required by law.